Description
Indication & Scope
AnRuiWei® Onradivir Tablets provides a treatment of uncomplicated influenza A in adult patients.
- Mechanism: Influenza A virus PB2 polymerase subunit inhibitor, a cap-binding antagonist that blocks viral mRNA transcription and early-stage replication of influenza A virus polymerase complex.
- Drug class: Oral anti-influenza viral PB2 inhibitor, prescription antiviral small-molecule medicine.
- Clinical use: Monotherapy for acute uncomplicated influenza A infection to shorten symptom duration and viral shedding time.
| Generic Name | Onradivir Tablets |
| Brand Name | AnRuiWei |
| Ingredient | Onradivir Tablets |
| Dosage Form | Tablets |
| Package | 0.2g*15 tablets/box |
| Conditions Treated | Acute uncomplicated influenza type A in adult patients |
| Taboos | Severe hypersensitivity to onradivir or tablet excipients; patients with influenza complicated by severe pneumonia or secondary bacterial sepsis |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 25°C±5°C, sealed and moisture-proof |
| Manufacturer | ZhongShengRuiChuang Biotechnology, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250019 |
| Approval Date | May 20, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Fixed daily oral dose administered for a short treatment course.
Time: Start treatment within 48 hours after the first onset of influenza symptoms for optimal efficacy.
Instructions for use: Swallow tablets whole, can be taken with or without meals; complete the full treatment course to avoid incomplete viral clearance.
Interaction: No major clinically significant drug interactions identified; concomitant use with live influenza vaccines is not advised during acute infection.
Side effects: Headache, dry mouth, mild diarrhea, fatigue, and transient elevated liver enzymes.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What infection does Onradivir Tablets treat?
It is used for the treatment of uncomplicated acute influenza A in adults.
What is the mechanism of Onradivir Tablets?
It inhibits the PB2 polymerase subunit of influenza A virus to block viral transcription and replication.
What is the best treatment time window of using Onradivir Tablets?
Treatment must be initiated within 48 hours after influenza symptom onset.
What patients are prohibited from using Onradivir Tablets?
Patients with severe influenza complicated with pneumonia and drug hypersensitivity cannot use it.
AnRuiWei® | Onradivir Tablets | Simple Influenza A | DengYueRX
INN: Onradivir Tablets
Indications: Simple Influenza A
Dosage Form: Tablets
Strength: 0.2g/tablet
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
